Posts

Posted on

Sofpironium Bromide for the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus. 2026 May 9;18(5):e108570. doi: 10.7759/cureus.108570. eCollection 2026 May.

ABSTRACT

Sofpironium bromide is a recently approved topical anticholinergic agent for primary axillary hyperhidrosis, developed using a retrometabolic approach to limit systemic side effects. However, randomized evidence about its effects has not yet been quantitatively synthesized. This meta-analysis aimed to assess the efficacy and safety of topical sofpironium bromide compared with a vehicle in patients with primary axillary hyperhidrosis. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) comparing topical sofpironium bromide with a vehicle. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random-effects models in Review Manager 7.2.0 (The Cochrane Collaboration, London, UK). Five RCTs, including 1,398 participants, were included, of whom 807 (57.7%) received topical sofpironium bromide. Compared with vehicle, sofpironium bromide significantly reduced gravimetric sweat production (GSP) at the end of treatment (MD -25.27 mg; 95% CI -40.15 to -10.40) and increased the likelihood of achieving at least a two-point improvement in the Hyperhidrosis Disease Severity Scale (HDSS) (RR 3.27; 95% CI 1.57-6.80). Discontinuation due to adverse events was more frequent in the sofpironium bromide group (RR 9.83; 95% CI 1.82-53.17). Adverse events occurred more frequently in the treatment group, including application-site dermatitis (RR 5.26; 95% CI 2.05-13.48), application-site pain (RR 4.63; 95% CI 2.08-10.28), pruritus (RR 5.97; 95% CI 1.98-18.02), and dry mouth (RR 15.45; 95% CI 5.35-44.62). No significant increase in serious adverse events was observed. Overall, this meta-analysis supports the efficacy of sofpironium bromide for primary axillary hyperhidrosis, while treatment decisions should be weighed against potential side effects.

PMID:42272574 | PMC:PMC13246317 | DOI:10.7759/cureus.108570

Posted on

Ultra-Minimally Invasive Medical Thoracoscopic Sympathectomy for Primary Palmar Hyperhidrosis

Ann Thorac Surg Short Rep. 2026 Mar 13;4(2):733-736. doi: 10.1016/j.atssr.2025.12.024. eCollection 2026 Jun.

ABSTRACT

Endoscopic thoracic sympathectomy is an effective treatment of primary palmar hyperhidrosis. Currently, single-port thoracoscopy is the primary surgical approach. Ensuring efficacy and safety, reducing surgical obstacles, minimizing tissue damage, and enhancing cosmesis and aesthetics of the surgical incision are focal in clinical research on endoscopic thoracic sympathectomy. Herein, we report a simple and minimally invasive surgical technique that avoids collisions due to the telescope and endodissector crossing in single-port thoracoscopic surgery. This refers to the application of medical thoracoscopy combined with nonintubation anesthesia and perfusion index monitoring in the treatment of primary palmar hyperhidrosis.

PMID:42267010 | PMC:PMC13245509 | DOI:10.1016/j.atssr.2025.12.024

Posted on

Risk factors for compensatory hyperhidrosis following CT-guided percutaneous radiofrequency sympathectomy: A retrospective observational study

Medicine (Baltimore). 2026 May 22;105(21):e48976. doi: 10.1097/MD.0000000000048976.

ABSTRACT

Compensatory hyperhidrosis (CH) is a significant complication following surgery for primary hyperhidrosis, impairing patients’ postoperative experience and quality of life. Radiofrequency sympathectomy (RFS) is one of the main minimally invasive surgeries for hyperhidrosis, yet high-risk factors and patient experiences of postoperative CH are rarely reported. This retrospective observational study (Strengthening the Reporting of Observational Studies in Epidemiology compliant) aimed to identify significant risk factors for CH after RFS and to develop a dynamic nomogram for individualized risk prediction. A total of 410 primary hyperhidrosis patients who underwent RFS between January 2018 and March 2023 were enrolled. A CH database was established via systematic follow-up to track postoperative sweating patterns. Detailed clinical assessments included the Numeric Rating Scale (NRS), Hyperhidrosis Disease Severity Scale (HDSS), and Hospital Anxiety and Depression Scale (HADS). Advanced statistical techniques, including logistic regression analysis, were used to identify potential risk factors for CH. Of the 410 patients, 281 (68.5%) developed CH, with 105 (25.6%) reporting moderate-to-severe symptoms. Multivariate analysis revealed 4 significant predictors of CH: male gender (odds ratio [OR] = 1.69); higher NRS scores (OR = 1.16); lower immediate postoperative HDSS (OR = 0.48); higher preoperative HADS scores (OR = 1.11). A dynamic, web-based nomogram was also developed to provide personalized CH risk prediction. Male gender, higher intraoperative NRS scores, lower immediate postoperative HDSS, and higher preoperative HADS scores were identified as independent risk factors. The constructed dynamic nomogram enables individualized risk prediction and supports clinicians in providing personalized preoperative counseling and perioperative management for patients undergoing RFS.

PMID:42175438 | DOI:10.1097/MD.0000000000048976

Posted on

Analysis of all video-assisted thoracic sympathectomy for hyperhidrosis over 9 years in Brazil: trends, costs and in-hospital mortality over 200 million inhabitants

Ann Vasc Surg. 2026 May 19:S0890-5096(26)00376-6. doi: 10.1016/j.avsg.2026.05.070. Online ahead of print.

ABSTRACT

BACKGROUND: Primary hyperhidrosis (HH) causes substantial functional and psychosocial impairment. While anticholinergic therapy has become first-line treatment, video-assisted thoracic sympathectomy (VATS) remains the only definitive option for patients with refractory disease. Large-scale, real-world data on the safety and utilization of VATS for HH at a national level remain limited.

METHODS: We conducted a nationwide retrospective analysis including all patients who underwent VATS for HH in Brazil between 2015 and 2023. Data were obtained from publicly available governmental databases encompassing both public and private healthcare systems. Procedure volumes, demographic characteristics, regional distribution, reimbursement, in-hospital mortality, and healthcare-sector differences were analyzed.

RESULTS: A total of 26,980 VATS procedures for HH were performed during the study period. Most patients were female (64.5%) and aged 15-39 years (82.7%). Procedures were predominantly performed in the private healthcare system (75.3%), with marked regional concentration in the Southeast (48.3%) and South (29.5%) regions. Overall in-hospital mortality was extremely low (0.048%) and did not differ significantly between public and private sectors. Despite similar safety profiles, the mean cost per procedure in the private system was substantially higher, resulting in more than 90% of total national expenditures.

CONCLUSIONS: In this nationwide cohort of nearly 27,000 procedures, VATS sympathectomy for primary hyperhidrosis demonstrated an low mortality rate across both public and private healthcare systems, supporting its role as a safe definitive surgical therapy when appropriately indicated. The marked disparities in access and cost highlight important system-level differences but do not appear to compromise procedural safety.

PMID:42162859 | DOI:10.1016/j.avsg.2026.05.070

Posted on

Living Through Sweat: A Qualitative Study of the Pre-Surgical Decision-Making Trajectory in Patients with Palmar Hyperhidrosis

Patient Prefer Adherence. 2026 May 4;20:589191. doi: 10.2147/PPA.S589191. eCollection 2026.

ABSTRACT

PURPOSE: This study aimed to explore the dynamic and ambivalent pre-surgical decision-making process of patients with palmar hyperhidrosis (PH), focusing on the “anxiety-sweating” feedback loop and the psychological factors influencing their treatment choices, particularly the interplay between psychological distress and the decision to pursue surgery.

PATIENTS AND METHODS: We conducted a qualitative descriptive phenomenological study in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ). Semi-structured in-depth interviews were conducted with 19 adults who had lived with PH for more than 10 years and were considering surgical treatment. All interviews were conducted before surgery. Data were analyzed using NVivo 11 software and Colaizzi’s seven-step phenomenological method.

RESULTS: Analysis revealed a four-stage pre-surgical journey. First, patients initially normalized excessive hand sweating as a personal difference or familial trait, but gradually developed disease awareness as symptoms persisted and intensified. Second, PH imposed a substantial psychosocial burden, including functional limitations in study, work, and daily life, as well as reduced self-confidence, anticipatory anxiety, and social avoidance. Many participants described a self-reinforcing “anxiety-sweating” vicious cycle. Third, dissatisfaction with conservative treatments and increasing access to treatment-related information prompted patients to move from temporary coping strategies toward consideration of more durable interventions. Fourth, surgical deliberation was characterized by ambivalence: patients hoped surgery would relieve symptoms and restore social confidence, while also expressing concerns regarding compensatory sweating, postoperative discomfort, and recovery.

CONCLUSION: The pathway toward surgical consideration in patients with palmar hyperhidrosis was a dynamic and ambivalent process shaped by symptom normalization, psychosocial burden, prior treatment experiences, and concerns about surgical risks. These findings highlight the importance of addressing psychological and social experiences alongside technical counseling and support the value of shared decision-making in pre-surgical care.

PMID:42109704 | PMC:PMC13155398 | DOI:10.2147/PPA.S589191

Posted on

The use of an objective method (continuous exosomatic electrodermal activity without external stimuli) to evaluate patients with hyperhidrosis undergoing video-assisted sympathectomy

Einstein (Sao Paulo). 2026 Apr 27;24:eAO1266. doi: 10.31744/einstein_journal/2026AO1266. eCollection 2026.

ABSTRACT

OBJECTIVE: To analyze continuous exosomatic electrodermal activity (EDA) without external stimuli (EDAcw) in patients with primary hyperhidrosis before and after sympathectomy.

METHODS: This prospective study included 28 participants, categorized into two groups. The first group comprised 18 patients with palmoplantar hyperhidrosis who underwent bilateral thoracic sympathectomy. The second group (control) consisted of 10 patients. Two questionnaires were administered: the Control Group completed them once, whereas the Sympathectomy Group completed them preoperatively, and on the first and thirtieth postoperative days. Sweating was evaluated by measuring EDAcw using an MP36R biosensor. Measurements were obtained from the hands and feet for 5 min without external stimuli in an air-conditioned environment and were performed preoperatively, and on the first and thirtieth postoperative days. Anthropometric, clinical, and surgical data were collected, and no significant sociodemographic differences were observed between the groups.

RESULTS: In the Sympathectomy Group, quality of life improved, and sweating reduced. During preoperative assessment, EDA was higher in the hands and feet of patients with hyperhidrosis than in the Control Group. Postoperatively, EDA in the hands decreased, with 100% of the patients showing a decrease in sweating. For the feet, 67% of the patients reported reduced sweating, and 44% showed a statistically significant decline in EDA.

CONCLUSION: Continuous exosomatic EDA measurement without external stimuli is a suitable method for assessing patients with palmoplantar hyperhidrosis and shows appropriate clinical correlation.

PMID:42054168 | DOI:10.31744/einstein_journal/2026AO1266

Posted on

Managing Antidepressant-Induced Hyperhidrosis With Vitamin E: An Over-the-Counter Supplement-Based Approach

Clin Case Rep. 2026 Mar 11;14(3):e71979. doi: 10.1002/ccr3.71979. eCollection 2026 Mar.

ABSTRACT

Excessive sweating is a common side effect of antidepressants, affecting approximately 22% of patients. Antidepressant-induced excessive sweating (ADIES) can significantly impair quality of life and medication adherence. This case report explores the use of Vitamin E as a novel adjunct treatment for ADIES. A woman in her 30s with major depressive disorder experienced significant improvement in depressive symptoms with venlafaxine but developed distressing night sweats at higher doses. Given the patient’s reluctance to switch to a different antidepressant and to reduce polypharmacy, a trial of over-the-counter Vitamin E was initiated based on its prior evidence in managing hot flashes in postmenopausal women. After 3 months, the patient reported a significant reduction in sweating, as measured by validated symptom severity scales (CGI-S and HDSS). The case highlights Vitamin E as a potentially effective, low-risk, and accessible option for ADIES, especially for patients at risk for polypharmacy. While larger studies are needed, Vitamin E may offer a simple strategy for improving quality of life and medication adherence.

PMID:42016646 | PMC:PMC13093336 | DOI:10.1002/ccr3.71979